| Prev Close | 10.23 |
| Day Low/High | 10.04 / 10.47 |
| 52 Wk Low/High | 6.50 / 25.10 |
| Avg Volume | 3.94M |
Cronos Group Inc. (CRON)
10.29
NASDAQ : Process Industries
| Exchange | NASDAQ |
| Shares Outstanding | 341.24M |
| Market Cap | 3.50B |
| EPS | -0.10 |
| P/E Ratio | 30.97 |
| Div & Yield | N.A. (N.A) |
Latest News
Cronos Group Could Break Key Moving Averages - Protect Long Positions
Let's look at the chart of CRON.
Morningstar High on Pot Growth, Sees U.S. Going Legal by 2023
Analysts say nation will turn a new leaf, changing federal law within a few years, as cannabis industry expected to grow big time over next decade.
Would You Rather Have an Executive Team Managing the Company or the Stock Price?
It all comes down to matching my time frame.
OrganiGram Could Climb Higher, but You Need Discipline Before Buying
Here's how to play OGI stock right now.
5 Cannabis ETFs to Fire Up Your Portfolio
Two of them are brand new.
Prohibition and the Paradoxical Proclivity of Cannabis Consumption
Is prohibition the real factor propping up projections for demand and pricing in the cannabis market?
Should Investors Buy the Dip in Canopy Growth Stock?
Canopy's earnings losses could just be a stepping stone to becoming the industry leader.
Canopy Growth Now Has to be Considered the Leader in the Canadian Cannabis Space
CGC has the best chance to transition to broader success should the U.S. ever go the route of legalization beyond the state level.
Cronos Group's High Times May Be About to Wear Off
Charts of this type are frequently found to be topping patterns.
Altria or Philip Morris International: Which Is the Better Dividend Stock?
While the two tobacco giants have similar yields, both also have very different businesses, with different growth potential in the years ahead.
Use Caution on Small-Caps, Plus Apple, Tesla and McDonald's: Market Recon
Equity markets marked time on Monday, mostly on light volume.
Cronos Group Certainly Qualifies for Mainstream Consideration
Revenue is where it's at for cannabis in 2019.
2 Big Earnings Reports I'll Be Watching This Week
A huge week is coming up for these well-known stocks.
7 Indirect Stock Plays on the Cannabis Sector
Investors can gain exposure to the high-flying cannabis industry without taking on undue risks.
Tilray Stock Lights Up as Partnerships Obscure Profitability Problem
The move was helped by the TLRY's deals with AB InBev for beverages and Novartis for medical applications.
Chart of the Day: Vetting the Value of Cannabis Companies
Assessing Aurora and its peers, strictly on the numbers.
Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot
In this day and age, companies must be 'disruptors' or get left in the dust.
Peltz Is the Perfect Problem Solver for Aurora Cannabis
Peltz's addition should pacify a persistent critique of the company.
Jim Cramer: Buy Aurora Cannabis Because Nelson Peltz Knows What Can Go Right
I know that Nelson is fascinated by the medicinal properties chiefly as a replacement for opioids, the scourge of this country.
Nelson Peltz Could Be Key to Cannabis in Consumer Packaged Goods
Aurora's prominent partner could be cannabis' key to breaking into consumer segments.
Melius Research Launches Cannabis Industry Coverage
In its first report on cannabis companies, Melius says prices are high.
Can Cronos Group Soar Higher? Looks Like it
The stock price of the cannabis company has been on a roll and is poised to move even higher still.
Jim Cramer: My Best Stock Picks for Cannabis and China
And why I won't recommend any other stocks in these markets, right now.
Short-Selling Is Really Hard. Just Ask Citron Research
Examining the influential short-sellers' big winners and losers provides important insights into trading and investing.
